Monitoring Laboratory Parameters in Acute Kidney Injury (AKI)

Importance of Electrolyte Monitoring in AKI

Electrolyte disorders are extremely common in AKI patients, with a cumulative incidence of up to 65% reported, especially among critically ill patients 1
Kidney failure is typically characterized by hyponatremia, hyperkalemia, hyperphosphatemia, and hypocalcemia, which can all contribute to increased mortality if not properly monitored and managed 2
Monitoring these parameters allows for early detection of imbalances and timely intervention, preventing life-threatening complications 3

Hyponatremia is common in AKI due to impaired water excretion 2
Sodium disturbances can lead to neurological complications, seizures, and increased mortality 1
Monitoring helps guide fluid management decisions, which are crucial in AKI management 4
Hyperkalemia is a life-threatening complication of AKI that can cause cardiac arrhythmias and sudden death 2
Hypokalemia can also occur in AKI patients on kidney replacement therapy (KRT), with reported prevalence up to 25% 2
Hypocalcemia and hyperphosphatemia are common in AKI due to impaired vitamin D metabolism and phosphate excretion 2
Hypophosphatemia has a high reported prevalence (60-80%) in ICU patients with AKI on KRT 2
These imbalances are associated with increased mortality, cardiac arrhythmias, respiratory failure, and prolonged mechanical ventilation 1
Calcium-phosphate product monitoring helps prevent precipitation in tissues and subsequent organ damage 3
Insulin resistance is highly prevalent among patients with AKI and is associated with increased mortality risk 5
High blood glucose concentration is one of the best independent predictors of mortality in AKI 5
Renal impairment increases risk of hypoglycemia as insulin is partially metabolized by the kidneys 5
Serum glucose levels should be maintained between 140-180 mg/dl in hospitalized patients with AKI 5
Tight glucose control (80-110 mg/dl) should not be pursued due to increased risk of hypoglycemia 5

Electrolytes should be monitored more frequently (every 6-12 hours) in critically ill AKI patients and those undergoing KRT 2
Patients on continuous KRT (CKRT) require even closer monitoring due to significant electrolyte shifts 2
Patients with AKI on chronic kidney disease (CKD) have higher risk of electrolyte abnormalities and require more vigilant monitoring 6
Monitoring should continue after hospital discharge, as AKI increases risk for long-term kidney dysfunction 4

Failure to monitor electrolytes frequently enough during KRT can lead to iatrogenic electrolyte disorders 2
Patients on medications affecting kidney function (ACE inhibitors, ARBs, diuretics) require more vigilant electrolyte monitoring, especially potassium 6
Overcorrection of electrolyte abnormalities can be as dangerous as the abnormalities themselves 1

The American College of Clinical Nutrition recommends that high blood glucose concentration in AKI patients is one of the best independent predictors of mortality in this clinical setting, but this reflects the severity of metabolic derangement rather than a causative pathway 7
AKI causes insulin resistance and hyperglycemia through peripheral insulin resistance and activation of hepatic gluconeogenesis, rather than hyperglycemia causing the kidney injury 8

AKI creates peripheral insulin resistance where increased glucose formation cannot be suppressed by exogenous nutrient supply, unlike in stable chronic kidney disease or healthy subjects 8
The kidney's role in insulin metabolism and glucose regulation becomes impaired, leading to both hyperglycemia risk and paradoxically increased hypoglycemia risk, although the exact mechanism is not fully understood 7
In critically ill patients with kidney failure, hypoglycemia (<60 mg/dl) occurs in 76% versus 35% in those with normal renal function 7
Severe hypoglycemia (<40 mg/dl) occurs in 29% of patients with kidney failure compared to 0% in those with normal renal function 7

Serum glucose levels should be maintained between 140-180 mg/dl in hospitalized patients with AKI, AKI on CKD, or CKD with kidney failure (Grade A recommendation, 96% consensus) 7
Tight glucose control (80-110 mg/dl) must not be pursued because of the dramatically increased risk of hypoglycemia (Grade A recommendation, 100% consensus) 7
Higher glycemic targets for patients with AKI contribute to reduction of hypoglycemia incidence in this population 7
Glycemic variability is increased in patients with kidney failure, requiring careful and frequent assessment 7
Rapid and sustained correction of hyperglycemia in diabetic patients with previous poor glycemic control may paradoxically worsen outcomes, as stated by the American Society of Nephrology 9

AKI creates profound insulin resistance through peripheral mechanisms and activation of hepatic gluconeogenesis that cannot be suppressed by exogenous nutrient supply, unlike in stable chronic kidney disease 10
The American Society of Nephrology recommends considering the metabolic impact of AKI on insulin requirements, as hyperglycemia in AKI is caused by both peripheral insulin resistance and increased hepatic glucose production, which may worsen as renal function deteriorates 10

CRRT solutions can provide substantial energy substrates that may reduce apparent insulin needs: citrate (3 kcal/g), glucose (3.4 kcal/g), and lactate (3.62 kcal/g) 11
The National Kidney Foundation suggests that energy gain from CRRT can be substantial, ranging from 115-1300 kcal/day depending on the type and rate of fluids used, with high lactate replacement fluids and ACD-A anticoagulation providing the most 11

Expect worsening insulin resistance as uremic toxins accumulate, potentially requiring higher insulin doses to maintain target glucose levels of 140-180 mg/dL, according to the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines 12
The American Diabetes Association recommends maintaining serum glucose between 140-180 mg/dL in all hospitalized AKI patients, regardless of CRRT status (Grade A recommendation) 12

If CRRT is initiated, consider the potential glucose provision from dialysate (up to 300 kcal/day with glucose-containing solutions) and improved clearance of insulin-resistance-inducing uremic toxins when calculating insulin requirements, as suggested by the European Renal Association 11
Factor in citrate-based anticoagulation energy provision (potentially 100-300 kcal/day) when calculating total insulin needs, according to the Clinical Nutrition guidelines 11